A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2019
Price : $35 *
At a glance
- Drugs Mirdametinib (Primary)
- Indications Neurofibromatoses; Plexiform neurofibroma
- Focus Therapeutic Use
- 30 Jul 2019 According to a SpringWorks Therapeutics media release, this trial was conducted by the Neurofibromatosis Clinical Trial Consortium.
- 03 Jun 2019 Results presented in a SpringWorks Therapeutics media release.
- 17 Dec 2018 Status changed from active, no longer recruiting to completed.